HC Wainwright Issues Pessimistic Forecast for RANI Earnings

Key Points

• HC Wainwright lowered its Q4 2026 EPS estimate for Rani Therapeutics to a loss of $0.06 per share from a projected loss of $0.05, while maintaining a “Buy” rating. Analysts expect continued losses through FY2029.
• Rani’s latest quarterly results exceeded expectations, with an EPS loss of $0.04 versus the consensus loss of $0.05 and revenue of $1.71 million compared with estimates of $0.93 million.
• The stock opened at $0.88, well below its 12-month high of $3.87. Despite the weak earnings outlook, analyst sentiment remains a “Moderate Buy,” with a consensus price target of $8.75; CEO Talat Imran also recently increased his stake by purchasing 35,000 shares.

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) - Equities research analysts at HC Wainwright lowered their Q4 2026 EPS estimates for Rani Therapeutics in a research report issued to clients and investors on Friday, August 21st. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.06) per share for the quarter, down from their previous estimate of ($0.05). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Rani Therapeutics' current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Rani Therapeutics' FY2027 earnings at ($0.20) EPS, FY2028 earnings at ($0.15) EPS and FY2029 earnings at ($0.24) EPS.

RANI has been the subject of several other research reports. Chardan Capital initiated coverage on Rani Therapeutics in a research note on Tuesday, August 18th. They set a "buy" rating for the company. Wall Street Zen upgraded shares of Rani Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, May 17th. Canaccord Genuity Group reissued a "buy" rating and issued a $5.00 price objective on shares of Rani Therapeutics in a research note on Wednesday, May 20th. Finally, Weiss Ratings downgraded shares of Rani Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Rani Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $8.75.

Rani Therapeutics Trading Down 0.1%

Rani Therapeutics stock opened at $0.88 on Tuesday. The stock has a 50 day moving average of $0.78 and a two-hundred day moving average of $0.95. Rani Therapeutics has a twelve month low of $0.44 and a twelve month high of $3.87. The stock has a market capitalization of $108.89 million, a price-to-earnings ratio of -3.26 and a beta of 0.78.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. The company had revenue of $1.71 million during the quarter, compared to analyst estimates of $0.93 million.

Insiders Place Their Bets

In other Rani Therapeutics news, CEO Talat Imran bought 35,000 shares of the company's stock in a transaction on Friday, July 17th. The shares were bought at an average price of $0.72 per share, for a total transaction of $25,200.00. Following the transaction, the chief executive officer owned 469,736 shares of the company's stock, valued at approximately $338,209.92. This trade represents a 8.05% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 26.73% of the company's stock.

Hedge Funds Weigh In On Rani Therapeutics

Hedge funds have recently bought and sold shares of the company. Stonepine Capital Management LLC purchased a new stake in Rani Therapeutics during the second quarter worth $2,670,190,000. Almitas Capital LLC acquired a new stake in Rani Therapeutics in the second quarter valued at $7,111,000. Seven Fleet Capital Management LP purchased a new position in shares of Rani Therapeutics in the second quarter valued at $1,011,299,000. Bank of America Corp DE purchased a new position in shares of Rani Therapeutics in the second quarter valued at $706,000. Finally, AWM Investment Company Inc. acquired a new position in shares of Rani Therapeutics during the 2nd quarter worth $5,703,000. 30.19% of the stock is owned by hedge funds and other institutional investors.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company's proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source